Variant:
rs4244285 at chr10:96541616 in CYP2C19 (VIP)

Alleles (on + chromosomal strand)
G > C
G > A
Amino Acid Translation
Pro227Pro
Alternate Names:
CYP2C19*2, CYP2C19:681G>A, CYP2C19:G681A, c.681G>A, c.681G>C, g.24154G>A, g.24154G>C, g.47346080G>A, g.47346080G>C
Haplotypes
This variant is used to determine: CYP2C19*2A, CYP2C19*2B, CYP2C19*2C, CYP2C19*2D

Clinical Annotations

To see the clinical annotation for this variant please register or sign in.

Variant Annotations

PharmGKB variant annotations provide information about variant-drug pairs based on individual PubMed publications. Each annotation represents information from a single paper and the goal is to report the information that the author states, not an interpretation of the paper. The PMID for supporting PubMed publications is found in the "Evidence" field.

Information presented, including study size, allele frequencies and statistics is taken directly from the publication. However, if the author does not correct p-values in cases of multiple hypotheses, curators may apply a Bonferroni correction. Curators attempt to report study size based on the actual number of participants used for the calculation of the association statistics, so the number may vary slightly from what is reported in the abstract of the paper. OMB Race Category information is derived from the paper and mapped to standardized categories. Category definitions may be found by clicking on the "OMB Race Category" link.

There are 38 annotations for this variant. Register or sign in to see them.

There are 4 disease-related annotations for this variant. Register or sign in to see them.

VIP Variant in CYP2C19

rs4244285 (c.681G>A) is the defining polymorphism of the CYP2C19*2 allele (previously referred to as CYP2C19m1) and is a synonymous G>A transition in exon 5 that creates an aberrant splice site. This change alters the mRNA reading frame, which results in a truncated, non-functional protein [Article:8195181]. CYP2C19*2 is the most common CYP2C19 loss-of-function allele, with allele frequencies of approximately 12% in Caucasians, 15% in African-Americans, and 29-35% in Asians [Article:21716271]. For more information see also CYP2C19*2 haplotype page.

Key Publications:
Drugs / Other Molecules

Appendix

Name: CYP2C19:681G>A
mRNA Variant & GenBank ID: G>A at 681 on NM_000769
Genomic Variant & GenBank ID: G>A at 21158 on AY796203.1
Protein Variant & GenBank ID: Pro>Pro at 227 on NP_000760
Key Haplotypes CYP2C19*2
gp: chr10:96531606(hg18)

Connected Drugs

Connected Drug Classes

Connected Diseases

Publications related to rs4244285 at chr10:96541616: 31

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart (British Cardiac Society). 2012. Oh Il-Young, et al. [Article:21700758@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and genomics. 2012. Harmsze Ankie M, et al. [Article:22228204@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. American heart journal. 2011. Gurbel Paul A, et al. [Article:21392617@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical Events as a Function of Proton Pump Inhibitor Use, Clopidogrel Use, and Cytochrome P450 2C19 Genotype in a Large Nationwide Cohort of Acute Myocardial Infarction: Results From the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Registry. Circulation. 2011. Simon Tabassome, et al. [Article:21262992@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Differential Impacts of CYP2C19 Gene Polymorphisms on the Antiplatelet Effects of Clopidogrel and Ticlopidine. Clinical pharmacology and therapeutics. 2011. Maeda A, et al. [Article:21178986@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response. Clinical pharmacology and therapeutics. 2011. Lewis J P, et al. [Article:21881565@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. European heart journal. 2011. Sibbing Dirk, et al. [Article:21527445@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. Heart (British Cardiac Society). 2011. Bouman Heleen J, et al. [Article:21628721@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. JAMA : the journal of the American Medical Association. 2011. Mega Jessica L, et al. [Article:22088980@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers. Journal of clinical pharmacology. 2011. Lee Seunghwan, et al. [Article:21383338@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19 variation and citalopram response. Pharmacogenetics and genomics. 2011. Mrazek David A, et al. [Article:21192344@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. British journal of cancer. 2010. Bray J, et al. [Article:20179710@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010. Wallentin Lars, et al. [Article:20801498@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010. Mega Jessica L, et al. [Article:20801494@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen. Pharmacogenomics. 2010. Ruiter Rikje, et al. [Article:21047200@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of cyclophosphamide and CYP2C19 polymorphism in Thai systemic lupus erythematosus. Rheumatology international. 2010. Ngamjanyaporn Pintip, et al. [Article:20358205@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. The New England journal of medicine. 2010. Paré Guillaume, et al. [Article:20979470@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. The pharmacogenomics journal. 2010. Sofi F, et al. [Article:20351750@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009. Voso Maria Teresa, et al. [Article:19638460@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. Drug metabolism and disposition: the biological fate of chemicals. 2009. Bohanec Grabar Petra, et al. [Article:19581389@PubMed]
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA : the journal of the American Medical Association. 2009. Shuldiner Alan R, et al. [Article:19706858@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. Journal of clinical psychopharmacology. 2009. Jaquenoud Sirot Eveline, et al. [Article:19593168@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cytochrome p-450 polymorphisms and response to clopidogrel. The New England journal of medicine. 2009. Mega Jessica L, et al. [Article:19106084@PubMed]
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. [Article:19106083@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients. Clinical pharmacology and therapeutics. 2008. Rudberg I, et al. [Article:17625515@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy research. 2006. Argikar Upendra A, et al. [Article:16815679@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clinical pharmacology and therapeutics. 2005. Schwab Matthias, et al. [Article:16338278@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. The Journal of infectious diseases. 2005. Haas David W, et al. [Article:16267764@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Therapeutic drug monitoring. 2005. van der Weide Jan, et al. [Article:16044105@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. The Journal of pharmacology and experimental therapeutics. 1998. Ibeanu G C, et al. [Article:9732415@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. The Journal of biological chemistry. 1994. de Morais S M, et al. [Article:8195181@PubMed]

Cross-References

UCSC Golden Path:
chr10:96541616
dbSNP:
rs4244285
ALFRED:
SI015423P
HapMap:
rs4244285

Platform Availability

  • Illumina

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.